Exploration of predictive biomarkers of nivolumab monotherapy in previously treated patients with advanced non-small cell lung cancer (NSCLC) and NSCLC patients with postoperative recurrence

Exploration of predictive biomarkers of nivolumab monotherapy in previously treated patients with advanced non-small cell lung cancer (NSCLC) and NSCLC patients with postoperative recurrence - Biomarker study on nivolumab monotherapy in previously treated patients with advanced NSCLC (GIFT-04/FIGHT-003)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026294

Enrollment

120

Registered

2017-04-01

Start date

2017-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced NSCLC and NSCLC with postoperative recurrence

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with Advanced NSCLC and NSCLC with postoperative recurrence who are treated with nivolumab monotherapy for 12 weeks in the institutions affiliated with Gumma-Ibaraki- Fukushima-Tochigi (GIFT) study group and/or Fukushima Investigative Group for Healing Thoracic Malignancy (FIGHT), and other cooperation hospitals between Apr.1, 2013 and Mar.31, 2017.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Potential predictive biomarkers of nivolumab monotherapy in previously treated patients with advanced NSCLC and NSCLC patients with postoperative recurrence.	—

Countries

Japan

Contacts

Public ContactHiroyuki Minemura

Fukushima Medical University, School of Medicine Department of Pulmonary Medicine

hiromine@fmu.ac.jp0245471111

Outcome results